|
Change of Director's Interest Notice
|
30 June 2023 at 4:55pm
|
|
HER-Vaxx induced antibodies correlated with tumour reduction
|
30 June 2023 at 9:05am
|
|
Imugene PD1-Vaxx patent extended to 2040
|
29 June 2023 at 9:05am
|
|
Initial Director's Interest Notice
|
23 June 2023 at 5:00pm
|
|
Imugene Appoints Kim Drapkin as Non-Executive Director
|
21 June 2023 at 8:55am
|
|
Imugene Advances VAXINIA MAST Trial to Next IV Cohorts
|
9 June 2023 at 9:20am
|
|
Imugene doses first combination patient in PD1-Vaxx trial
|
1 June 2023 at 9:30am
|
|
Imugene Investor Webinar - FDA IND Clearance for onCARlytics
|
19 May 2023 at 12:50pm
|
|
FDA clears Imugene IND for onCARlytics first-in-class study
|
19 May 2023 at 9:00am
|
|
onCARlytics with ARTEMIS T cells show anti-tumour activity
|
18 May 2023 at 9:25am
|
|
onCARlytics with Artemis T cells abstract presented at ASGCT
|
3 May 2023 at 9:05am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 April 2023 at 8:40am
|
|
Imugene receives $12.6m R&D tax refund
|
26 April 2023 at 9:30am
|
|
Imugene Images and Follows CHECKVacc in TNBC Patients
|
20 April 2023 at 8:55am
|
|
First patients dosed in IT & IV cohort 3 of VAXINIA trial
|
5 April 2023 at 10:05am
|
|
Imugene Presentation to NWR Healthcare Conference
|
22 March 2023 at 10:10am
|
|
Imugene to present at NWR Virtual Healthcare Conference
|
16 March 2023 at 10:25am
|
|
Imugene Corporate Presentation
|
15 March 2023 at 12:20pm
|
|
Notice Under Section 708A
|
10 March 2023 at 5:40pm
|
|
Notification regarding unquoted securities - IMU
|
10 March 2023 at 5:30pm
|
|
Application for quotation of securities - IMU
|
10 March 2023 at 5:30pm
|
|
Change of Registered Office
|
8 March 2023 at 10:15am
|
|
First Patients Dosed in Combination Study of VAXINIA
|
3 March 2023 at 10:05am
|
|
Imugene appoints CFO Mike Tonroe as Company Secretary
|
2 March 2023 at 2:35pm
|
|
Half Yearly Report and Accounts
|
28 February 2023 at 12:35pm
|
|
Application for quotation of securities - IMU
|
22 February 2023 at 6:00pm
|
|
Imugene PD1-Vaxx Immunotherapy Patent Granted in the US
|
10 February 2023 at 9:10am
|
|
Imugene VAXINIA trial advances to Combination Cohort
|
2 February 2023 at 10:15am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
27 January 2023 at 10:15am
|
|
HER-Vaxx and CF33 Platforms Featured at ASCO Symposium
|
20 January 2023 at 9:30am
|
|
Imugene Presentation to the JP Morgan Healthcare Conference
|
9 January 2023 at 10:05am
|
|
Imugene Receives Vaxinia Ethics Approval in Australia
|
9 January 2023 at 9:55am
|
|
Letter to Shareholders
|
6 January 2023 at 10:50am
|
|
Notification regarding unquoted securities - IMU
|
22 December 2022 at 4:05pm
|
|
Notification regarding unquoted securities - IMU
|
22 December 2022 at 3:55pm
|
|
Ceasing to be a substantial holder
|
22 December 2022 at 2:45pm
|
|
Ceasing to be a substantial holder
|
20 December 2022 at 2:10pm
|
|
Change of Director's Interest Notice x6
|
20 December 2022 at 2:10pm
|
|
Notification of cessation of securities - IMU
|
16 December 2022 at 6:00pm
|
|
Notification regarding unquoted securities - IMU
|
16 December 2022 at 5:55pm
|
|
Imugene HER-Vaxx and CF33 Platforms To Feature at ASCO
|
16 December 2022 at 10:15am
|
|
Imugene to Present at J.P. Morgan Healthcare Conference
|
12 December 2022 at 12:05pm
|
|
CHECKVacc Data Presented at the 2022 SABC Symposium
|
9 December 2022 at 9:55am
|
|
Appendix 3H
|
6 December 2022 at 5:15pm
|
|
Notice Under Section 708A
|
5 December 2022 at 4:15pm
|
|
Appendix 2A
|
5 December 2022 at 4:15pm
|
|
First Patient Dosed in VAXINIA Intravenous Cohort 2
|
5 December 2022 at 10:10am
|
|
Positive New HER-Vaxx HERIZON Data Presented at ESMO Asia
|
5 December 2022 at 9:55am
|
|
Application for quotation of securities - IMU
|
25 November 2022 at 5:00pm
|
|
Application for quotation of securities - IMU
|
18 November 2022 at 3:00pm
|
Imugene